MODEL SPOTLIGHT | Pan02: A Murine Model of Pancreatic Cancer
Pancreatic cancer is the ninth most commonly diagnosed cancer and ranks as one of the deadliest with the lowest 5-year survival rate of 5-8%. At diagnosis, a vast majority of pancreatic ductal adenocarcinoma (PDAC) patients have either locally advanced, unresectable, or metastatic disease. As current treatments offer limited benefits to pancreatic cancer patients, newer options like immunotherapy drugs are now being tested in clinical trials.
Following along the lines of current clinical trials; in the preclinical platform, we are evaluating single and combination therapies using the Pan02 murine PDAC model. Pan02 is a well-established Grade III adenocarcinoma model developed by chemical induction. In this model spotlight we present in vivo data on the Pan02 tumor model including:
- Growth kinetics
- Response to immunomodulatory antibodies
- Focal radiation
- Combination of radiation therapy with immune modulatory agents